Nurses Compass
Drug Guide
Ansuvimab-zykl
Classification
Therapeutic: Antiviral agent
Pharmacological: Monoclonal antibody
FDA Approved Indications
- Treatment of Ebola Virus Disease in adults and children
Mechanism of Action
Ansuvimab-zykl is a monoclonal antibody that targets the glycoprotein of the Ebola virus, neutralizing the virus and preventing it from entering cells, thereby inhibiting viral replication.
Dosage and Administration
Adult: Loading dose of 50 mg/kg administered intravenously over 60 minutes, with the possibility of additional doses based on clinical response.
Pediatric: Same dosing as adults, based on weight. Detailed dosing should be guided by clinical protocol.
Geriatric: No specific adjustments recommended, but caution advised due to potential comorbidities.
Renal Impairment: No specific dosage adjustments required.
Hepatic Impairment: No specific data available.
Pharmacokinetics
Absorption: Administered intravenously, so absorption is complete.
Distribution: Widely distributed in body fluids, with a large volume of distribution typical of monoclonal antibodies.
Metabolism: Metabolized by proteolytic degradation into amino acids.
Excretion: Excreted via catabolic pathways, not affected by renal function.
Half Life: Approximately 15 days.
Contraindications
- Hypersensitivity to ansuvimab-zykl or any component of the formulation.
Precautions
- Use with caution in patients with a history of allergic reactions to monoclonal antibodies. Monitoring during infusion recommended.
Adverse Reactions - Common
- Infusion-related reactions (fever, chills, hypotension) (Unknown, but monitoring required)
- Headache (Unknown)
- Nasal congestion (Unknown)
Adverse Reactions - Serious
- Anaphylaxis (Rare)
- Serious infusion reactions (Rare)
Drug-Drug Interactions
- No specific interactions identified at this time.
Drug-Food Interactions
- No known food interactions.
Drug-Herb Interactions
- Limited data; caution advised with concomitant herbal products.
Nursing Implications
Assessment: Monitor for infusion-related reactions, allergic responses, and overall clinical response.
Diagnoses:
- Risk for allergic reaction
- Risk for infusion-related reactions
Implementation: Administer as an intravenous infusion in a controlled setting with resuscitation equipment available.
Evaluation: Monitor patient for resolution of symptoms and adverse reactions post-infusion.
Patient/Family Teaching
- Inform about possible reactions during and after infusion.
- Report any signs of allergic reactions such as rash, difficulty breathing, or swelling.
- Follow outpatient instructions if discharged shortly after infusion.
Special Considerations
Black Box Warnings:
- None identified at this time.
Genetic Factors: None relevant to pharmacokinetics or pharmacodynamics.
Lab Test Interference: No significant interference expected.
Overdose Management
Signs/Symptoms: Potential for exaggerated infusion reactions or hypersensitivity.
Treatment: Discontinue infusion immediately, provide supportive care, and manage allergic reactions as needed.
Storage and Handling
Storage: Store in a refrigerator at 2-8°C (36-46°F).
Stability: Stable until the expiration date indicated on the vial.